A Multi-center, Randomized, Double-Blinded Study of the Efficacy and Safety of Lubiprostone in Patients With Opioid-induced Bowel Dysfunction (OBD)
Latest Information Update: 17 Dec 2019
At a glance
- Drugs Lubiprostone (Primary)
- Indications Constipation
- Focus Registrational; Therapeutic Use
- Sponsors Sucampo Pharmaceuticals
- 28 Aug 2017 Results of post-hoc pooled analysis of this and other 5 studies published in the Digestive Diseases and Sciences.
- 01 May 2013 OPAL is a trial programme, please do not add it as an acronym.
- 01 May 2013 New trial record